+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Lessons learned from hyponatremia associated with hyperthermic intraperitoneal chemoperfusion with oxaliplatin



Lessons learned from hyponatremia associated with hyperthermic intraperitoneal chemoperfusion with oxaliplatin



Peritoneal Dialysis International 28(1): 32-34




(PDF emailed within 1 workday: $29.90)

Accession: 054107722

Download citation: RISBibTeXText

PMID: 18178945


Related references

Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Peritoneal Dialysis International 28(1): 61-66, 2008

Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer ChemoTherapy and Pharmacology 74(3): 571-582, 2014

Rapid correction of severe hyperglycaemia during hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Acta Chirurgica Belgica 109(2): 256-259, 2009

Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin. European Journal of Surgical Oncology 39(7): 754-759, 2013

Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Annals of Surgical Oncology 15(2): 535-541, 2007

Hyperthermic intraperitoneal chemoperfusion with high dose oxaliplatin: Influence of perfusion temperature on postoperative outcome and survival. F1000research 2(): 179-179, 2013

A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Annals of Surgical Oncology 15(8): 2137-2145, 2008

Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer. Journal of ChemoTherapy 28(3): 203-209, 2015

Morbidity and mortality of hyperthermic intraperitoneal chemoperfusion. Der Chirurg; Zeitschrift für Alle Gebiete der Operativen Medizen 84(11): 957-961, 2014

Patient selection for cytoreduction and hyperthermic intraperitoneal chemoperfusion. Cancer Treatment and Research 134: 215-229, 2007

An overview of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for the anesthesiologist. Anesthesia and Analgesia 116(4): 924-931, 2013

Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Annals of Surgical Oncology 11(4): 387-392, 2004

The randomized trial of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion: what it does and does not tell us. Annals of Surgical Oncology 15(10): 2633-2635, 2008

Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. Cancer Treatment and Research 82: 211-219, 1996

A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Medicine 2(3): 334-342, 2014